Constantinos T. Sofocleous, MD, PhD
Interventional Oncology; Interventional Radiology; Image-Guided Therapies
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Sofocleous accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
Memorial Sloan Kettering is a designated Blue Distinction Center for bone marrow transplant and CAR-T.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment. In-network participation exceptions include:
- Emblem’s HIP Commercial Millennium, Select Care and Enhanced Care Prime networks is not in-network with Memorial Sloan Kettering.
- Please call Emblem to confirm if your specific plan is in-network.
For information regarding Memorial Sloan Kettering’s participation with Emblem’s Medicare Advantage Plans, please refer to the Medicare & Medicaid page
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York Indemnity, HMO, EPO, PPO, POS and Medicare Advantage plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Please call Empire BCBS to confirm if your specific plan is in-network with Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
For our NJ locations, Memorial Sloan Kettering is an in-network provider with most Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. Horizon members with Blue Card Access (there would be a suitcase logo on the front of the card) may have access to our NY locations. Please call Horizon to confirm if your plan is in-network in NY.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
For information about Medicare and Medicaid, please visit this page
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
Most Blue Cross Blue Shield plans include Memorial Sloan Kettering as an in-network provider. Contact your insurance company to confirm if Memorial Sloan Kettering is in-network.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
MD, PhD, University of Athens School of Medicine (Greece)
St. Luke's-Roosevelt Hospital Center; Columbia University College of Physicians and Surgeons
NYU Medical Center
Radiology; CAQ Vascular and Interventional Radiology
I am an interventional radiologist specializing in interventional oncology, caring for people with cancer. I have been practicing interventional radiology since 1998 and joined the Interventional Radiology Service at Memorial Sloan Kettering in 2002. As an expert in interventional oncology, I use minimally invasive, image-guided procedures to diagnose and treat patients with cancer with minimal side effects, complications, and discomfort.
My expertise include the treatment of primary and metastatic liver and lung cancers using thermal ablation (radiofrequency, microwave, cryoablation) or other non-thermal sources of energy (NanoKnife ® or irreversible electroporation). I also specialize in catheter-directed therapies that treat malignant liver tumors that cannot be removed through surgery or destroyed locally (ablation). These treatments include embolization techniques that use beads alone or combined with chemotherapy or radiotherapy delivered directly into liver tumors. These beads combine the therapeutic effects of radiation (radio embolization or selective internal radiation therapy) or chemotherapy (DEB-TACE or chemoembolization) with that of small particle tumor microvasculature embolization. These approaches offer the best therapeutic option to people with cancer who are not candidates for surgery or ablation.
I lecture nationally and internationally on topics such as embolization, radio embolization, and ablation of liver tumors — particularly metastases from colorectal, breast, or other primary cancers as well as hepatocellular cancer. I have also lectured extensively on ablation as a treatment for primary and metastatic lung cancers.
I am involved in several multidisciplinary clinical, research, and educational activities at MSK. As a faculty member on the hepatobiliary, colorectal, and solid-tumor teams, I work very closely with a team of hepatobiliary, colon, and thoracic surgeons; gastrointestinal, breast, and other oncologists; and gastroenterologists and radiation therapists to determine the most appropriate treatment for patients with primary and metastatic cancer of the liver and lung. I am also a current member of the Institutional Review Board, which is responsible for reviewing all human subjects’ related research and monitoring ongoing research conducted at MSK to ensure compliance with regulations.
My research interest is the assessment, validation, and development of biomarkers and surrogate imaging biomarkers. These can predict outcomes and help stratify patients undergoing ablation and imaging-guided locoregional therapies of tumors in general, and particularly in colon cancer metastases. I have published extensively on the treatment of colorectal, neuroendocrine, and breast cancer liver metastases treated by image-guided therapies including radiofrequency and microwave ablation, irreversible electroporation, small particle bland embolization, and radio embolization or selective internal radiation therapy with Yttrium 90 microspheres. I have also studied and published on the cellullar effects of ablation on liver tumors, the use of embolization to salvage infusion pumps in patients with colon cancer metastatic to the liver, and the use of drug eluding beads (DEB-TACE) to treat primary liver cancer. Currently, I am the MSK site primary investigator, along with medical oncologist Andrea Cercek, of a new multi-institutional, randomized controlled trial where we assess the value of treating people with colorectal cancer liver metastases with Yttrium 90 glass microspheres in addition to standard of care second-line chemotherapy. I am also the primary investigator of an ongoing study examining tissue before and after thermal ablation of colon cancer liver metastases to detect predictive biomarkers that can impact treatment outcomes. This study was initially supported through an NIH R21 grant and showed that biopsies after radiofrequency ablation can predict outcomes.
Despite my strong interest in research, my main focus remains caring for patients. Every cancer has a unique identity, so treatment must be tailored to each patient and each situation. The environment and philosophy of MSK allow me and my partners in interventional oncology and image-guided therapies to offer each patient the best possible care for their cancer. The combination of excellence in clinical work and research also allows us to design important and pivotal clinical trials that directly translate in the best patient care.
Awards and Honors
- Radiological Society of North America Interventional Radiology Research Trainee Prize (1997)
- Roentgen Resident Research Award (1998)
- Fellow, Society of Interventional Radiology (2005)
- Fellow, Cardiovascular and Interventional Radiological Society of Europe (2013)
- Clinical Trials Investigated by Dr. Sofocleous
- A Study Using Tissue Biopsy and PET Scanning to Optimize Thermal Ablation for Colon Cancer Liver Metastases
- Examination of Tissue from Ablated Malignant Liver Metastases to Predict Outcome
- Examination of Tissue from Ablated Malignant Liver Metastases to Predict Outcome
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Visit PubMed for a full listing of Dr. Sofocleous’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
At MSK, we’re committed to delivering the best care to every patient. We use feedback from our patients to continue to improve our care. We also post patient reviews online to help you make healthcare choices. Learn more about our patient experience reviews.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Constantinos T. Sofocleous discloses the following relationships and financial interests:
Varian Medical Systems
Provision of Services
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.